Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.

BACKGROUND Dipeptidyl peptidase 4 (DPP4) inhibitors are used for treatment of diabetes mellitus (DM). We hypothesized that sitagliptin, a DPP4-inhibitor, could improve endothelial dysfunction in DM patients with coronary artery disease (CAD). METHODS AND RESULTS The 40 patients with CAD and uncontrolled DM, aged 68.7±9.4 years (mean±standard deviation) (50% males, hemoglobin A1c [HbA1c] 7.4±1.0%) were assigned to either additional treatment with sitagliptin (50 mg/day, n=20) or aggressive conventional treatment (control, n=20) for 6 months. Endothelial function was assessed by the reactive hyperemia peripheral arterial tonometry index (RHI). The clinical characteristics at baseline were not different between the groups. After treatment, fasting blood glucose and insulin levels, and lipid profiles were not different between the groups. HbA1c levels significantly improved similarly in both groups. The percent change in RHI was greater in the sitagliptin group than in the control group (62.4±59.2% vs. 15.9±22.0%, P<0.01). Furthermore, treatment with sitagliptin resulted in a significant decrease in the high-sensitivity C-reactive protein (hsCRP) level, but no such change was noted in the control group. Linear regression analysis demonstrated a significant negative relation between changes in RHI and hsCRP, but not between RHI and HbA1c. CONCLUSIONS Sitagliptin significantly improved endothelial function and inflammatory state in patients with CAD and uncontrolled DM, beyond its hypoglycemic action. These findings suggest that sitagliptin has beneficial effects on the cardiovascular system in DM patients. 

[1]  P. Libby Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[2]  P. Dandona,et al.  Sitagliptin exerts an antinflammatory action. , 2012, The Journal of clinical endocrinology and metabolism.

[3]  G. Paolisso,et al.  Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes , 2012, Diabetes Care.

[4]  I. Saito Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[5]  Y. Izumiya,et al.  A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. , 2012, Journal of the American College of Cardiology.

[6]  B. Maron,et al.  Subcellular localization of oxidants and redox modulation of endothelial nitric oxide synthase. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[7]  Å. Sjöholm,et al.  Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor , 2010, Molecular and Cellular Endocrinology.

[8]  S. Umemura,et al.  Digital assessment of endothelial function and ischemic heart disease in women. , 2010, Journal of the American College of Cardiology.

[9]  A. Avogaro,et al.  The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes , 2010, Diabetes Care.

[10]  S. Colan,et al.  Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents. , 2009, The Journal of pediatrics.

[11]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  Robert David,et al.  Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. , 2009, Cell stem cell.

[13]  Ramachandran S Vasan,et al.  Cross-Sectional Relations of Digital Vascular Function to Cardiovascular Risk Factors in the Framingham Heart Study , 2008, Circulation.

[14]  A. Avogaro,et al.  Endothelial progenitor cells in the natural history of atherosclerosis. , 2007, Atherosclerosis.

[15]  Nick D. Tsihlis,et al.  The role of nitric oxide in the pathophysiology of intimal hyperplasia. , 2007, Journal of vascular surgery.

[16]  D. Drucker Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes , 2007, Diabetes Care.

[17]  S. Grundy,et al.  Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus , 2006, Diabetes Care.

[18]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[19]  Amir Lerman,et al.  Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. , 2004, Journal of the American College of Cardiology.

[20]  J. Holst,et al.  Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. , 2004, American journal of physiology. Endocrinology and metabolism.

[21]  Geoffrey C Gurtner,et al.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.

[22]  Dennis D. Kim,et al.  Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  Ayan R Patel,et al.  Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. , 2003, American heart journal.

[24]  R. Roman,et al.  Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats , 2003, Journal of hypertension.

[25]  Amir Lerman,et al.  Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. , 2003, Journal of the American College of Cardiology.

[26]  Andrew C. Li,et al.  The macrophage foam cell as a target for therapeutic intervention , 2002, Nature Medicine.

[27]  J. Keaney,et al.  Endothelial function: a barometer for cardiovascular risk? , 2002, Circulation.

[28]  T. Lüscher,et al.  Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. , 1998, Circulation.

[29]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[30]  G. Gensini,et al.  A more meaningful scoring system for determining the severity of coronary heart disease. , 1983, The American journal of cardiology.